Research by Dr Farhat Mirza

All of our attendees carry out a piece of research in an area of MS clinical practice or treatment that interests them.

This snapshot gives you a quick idea of what they found and why. If you want to learn more, just click through to the full research report, or follow the links within the snapshot.

If you would like to contact the alumni who did the research, drop us a line and we’ll put you in touch where possible.

 

Aim

To create a database for the group of patients with MS receiving disease-modifying treatments (DMTs) at Royal Preston Hospital, so that management of the treatment can be effectively monitored, leading to better clinical care and more efficient professional practice.

Headlines

  • The Royal Preston Hospital is the regional centre for neurology in Lancashire, with a population of over one million. It is the centre of treatment for MS and manages all disease-modifying treatments (DMTs).
  • We studied a random sample of clinic letters from a group of 253 patients on DMTs.
  • By auditing, we can optimise how we manage treatment and can measure ourselves against national standards and other centres of care.

Key findings

  • Most of the patients in the sample were female.
  • Mostly, two relapses were seen before being treated with a first-line DMT.
  • The DMT Copaxone was most widely used.
  • It was common for patients to be escalated to a DMT after a single relapse, broadly in keeping with current guidelines.

Core recommendations

  • Repeat the same audit with a larger population size.
  • Present the findings to the hospital to discuss the implications to cost and quality of patient care.

 

Take action

  • Read the full report
  • Contact the researcher to discuss their work (please put the name of the Snapshot as your title in our contact form)
  • Learn more about the issues raised in this report. Click the scattered links to access further information.